Optinose price target adjusted for stock split at Lake Street

Lake Street analyst Thomas Flaten lowered the firm’s price target on Optinose (OPTN) to $17 from $45 and keeps a Buy rating on the shares, saying that “in part accounting for the recent 1-for-15 reverse stock split, we revised our $3 price target to $17″ after OptiNose delivered preliminary XHANCE revenue for Q4 of $22.4M, which was above the firm’s and consensus estimates.